Baker Bros. Advisors’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,096,210
| Closed | -$4.59M | – | 95 |
|
|
2025
Q2 | $4.59M | Buy |
4,096,210
+953
| +0% | +$1.16K | 0.04% | 69 |
|
|
2025
Q1 | $4.71M | Buy |
4,095,257
+953
| +0% | +$1.77K | 0.05% | 59 |
|
|
2024
Q4 | $25M | Buy |
4,094,304
+1,994
| +0% | +$23.7K | 0.27% | 41 |
|
|
2024
Q3 | $67.7M | Buy |
4,092,310
+1,994
| +0% | +$21.8K | 0.7% | 22 |
|
|
2024
Q2 | $28.1M | Buy |
4,090,316
+1,994
| +0% | +$17.1K | 0.36% | 35 |
|
|
2024
Q1 | $39.5M | Buy |
4,088,322
+397,311
| +11% | +$4.6M | 0.49% | 31 |
|
|
2023
Q4 | $30.7M | Buy |
3,691,011
+533,247
| +17% | +$3.1M | 0.35% | 33 |
|
|
2023
Q3 | $26.4M | Buy |
3,157,764
+554
| +0% | +$4.7K | 0.15% | 32 |
|
|
2023
Q2 | $29.1M | Buy |
3,157,210
+554
| +0% | +$6.21K | 0.17% | 33 |
|
|
2023
Q1 | $43.4M | Buy |
3,156,656
+554
| +0% | +$11.5K | 0.24% | 24 |
|
|
2022
Q4 | $53.7M | Hold |
3,156,102
| – | – | 0.32% | 24 |
|
|
2022
Q3 | $71.8M | Hold |
3,156,102
| – | – | 0.47% | 20 |
|
|
2022
Q2 | $56.9M | Hold |
3,156,102
| – | – | 0.32% | 20 |
|
|
2022
Q1 | $84.4M | Hold |
3,156,102
| – | – | 0.48% | 17 |
|
|
2021
Q4 | $92.6M | Hold |
3,156,102
| – | – | 0.45% | 20 |
|
|
2021
Q3 | $208M | Hold |
3,156,102
| – | – | 0.91% | 13 |
|
|
2021
Q2 | $263M | Hold |
3,156,102
| – | – | 1.15% | 11 |
|
|
2021
Q1 | $242M | Buy |
3,156,102
+11,210
| +0.4% | +$1.02M | 1.05% | 13 |
|
|
2020
Q4 | $278M | Buy |
3,144,892
+446
| +0% | +$31.4K | 1.05% | 14 |
|
|
2020
Q3 | $232M | Buy |
3,144,446
+223
| +0% | +$13.2K | 0.93% | 14 |
|
|
2020
Q2 | $230M | Buy |
3,144,223
+223
| +0% | +$13.5K | 1.01% | 13 |
|
|
2020
Q1 | $177M | Hold |
3,144,000
| – | – | 1.09% | 9 |
|
|
2019
Q4 | $120M | Hold |
3,144,000
| – | – | 0.64% | 18 |
|
|
2019
Q3 | $55.8M | Buy |
+3,144,000
| New | +$63.5M | 0.38% | 21 |
|
Other funds holding IGMS
Baker Bros. Advisors's IGMS Position: Q3 2025 in Review
Baker Bros. Advisors sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 4,096,210 shares — an estimated $4.59M sold.
Baker Bros. Advisors first reported a position in IGMS in Q3 2019 and held it in 24 quarters. The position peaked at $278M in Q4 2020. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- Baker Bros. Advisors reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- Baker Bros. Advisors sold 4,096,210 IGM Biosciences shares in Q3 2025, an estimated $4.59M.
- Baker Bros. Advisors first reported a position in IGM Biosciences in Q3 2019 and held it in 24 quarters.
- Baker Bros. Advisors's IGM Biosciences position peaked at $278M in Q4 2020.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on Baker Bros. Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.